Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Status: | Completed |
---|---|
Conditions: | Renal Impairment / Chronic Kidney Disease, Anemia |
Therapuetic Areas: | Hematology, Nephrology / Urology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/14/2018 |
Start Date: | July 30, 2012 |
End Date: | October 19, 2017 |
A phase 3, multicenter, randomized, double-blind, parallel group study. Anemic subjects with
chronic kidney disease (CKD) and not on dialysis will be randomized 1:1 to 1 of 2 dosing
strategies to evaluate the proportion of subjects receiving at least one red blood cell (RBC)
transfusion. In the haemoglobin (Hb)-based titration group, darbepoetin alfa doses will be
titrated to maintain Hb ≥ 10.0 grams/deciliter (g/dL). In the fixed dose group, subjects will
receive a fixed dose of darbepoetin alfa. Treatment group, darbepoetin alfa doses, and
protocol specified Hb concentrations will be blinded. Subjects will be followed for
approximately 2 years from the date of randomization.
chronic kidney disease (CKD) and not on dialysis will be randomized 1:1 to 1 of 2 dosing
strategies to evaluate the proportion of subjects receiving at least one red blood cell (RBC)
transfusion. In the haemoglobin (Hb)-based titration group, darbepoetin alfa doses will be
titrated to maintain Hb ≥ 10.0 grams/deciliter (g/dL). In the fixed dose group, subjects will
receive a fixed dose of darbepoetin alfa. Treatment group, darbepoetin alfa doses, and
protocol specified Hb concentrations will be blinded. Subjects will be followed for
approximately 2 years from the date of randomization.
The study is a phase 3, multicenter, randomized, double-blind, parallel group study designed
to describe the benefits and potential risks of a new treatment strategy using a fixed dose
of darbepoetin alfa in subjects with CKD and not on dialysis. Anemic subjects without recent
use of an erythropoiesis stimulating agent (ESA) will be randomly allocated 1:1 to treatment
with a fixed dose of darbepoetin alfa or to treatment with darbepoetin alfa using a Hb-based
titration strategy, which has been the conventional dosing strategy. In the Hb-based
titration group, darbepoetin alfa doses will be titrated to maintain Hb ≥ 10.0 g/dL. This
study aims to estimate the incidence of RBC transfusions (administered as deemed clinically
necessary) in each group and the difference in incidence of RBC transfusions between the 2
groups. In addition, multiple aspects, such as cumulative darbepoetin alfa dose, total number
of units of transfusions, Hb concentration, Hb-related parameters (eg, Hb variability,
excursions, rate of change), and adverse (eg, cardiovascular) events, will also be considered
in order to determine a preferred dosing regimen. Treatment group, darbepoetin alfa doses,
and protocol specified Hb concentrations will be blinded to the investigator, subjects and
study team. Subjects will be followed for approximately 2 years from the date of
randomization.
to describe the benefits and potential risks of a new treatment strategy using a fixed dose
of darbepoetin alfa in subjects with CKD and not on dialysis. Anemic subjects without recent
use of an erythropoiesis stimulating agent (ESA) will be randomly allocated 1:1 to treatment
with a fixed dose of darbepoetin alfa or to treatment with darbepoetin alfa using a Hb-based
titration strategy, which has been the conventional dosing strategy. In the Hb-based
titration group, darbepoetin alfa doses will be titrated to maintain Hb ≥ 10.0 g/dL. This
study aims to estimate the incidence of RBC transfusions (administered as deemed clinically
necessary) in each group and the difference in incidence of RBC transfusions between the 2
groups. In addition, multiple aspects, such as cumulative darbepoetin alfa dose, total number
of units of transfusions, Hb concentration, Hb-related parameters (eg, Hb variability,
excursions, rate of change), and adverse (eg, cardiovascular) events, will also be considered
in order to determine a preferred dosing regimen. Treatment group, darbepoetin alfa doses,
and protocol specified Hb concentrations will be blinded to the investigator, subjects and
study team. Subjects will be followed for approximately 2 years from the date of
randomization.
Key Inclusion Criteria:
- Clinical history of advanced CKD not on dialysis with at least 1 historic estimated
glomerular filtration rate (eGFR) < 45.0 mL/mi)/1.73 m2 at least 12 weeks prior to
screening
- Not currently receiving dialysis with an eGFR < 45.0 mL/min/1.73m2, per the central
laboratory during screening
- Chronic anemia due to renal failure
- Two Hb concentrations < 10.0 g/dL, at least 2 weeks apart during screening using the
modified Hb point of care (POC) device
- Iron replete, defined as a transferrin saturation (TSAT) ≥ 20% and a ferritin ≥ 100
ng/mL, per the central laboratory during screening
- Vitamin B12 and folate replete, defined as a vitamin B12 level > 180 pg/mL and a
folate concentration > 7 nmol/L, per the central laboratory during screening
- Clinically stable in the opinion of the investigator
- Subject has provided written informed consent
Key Exclusion Criteria:
- Systemic hematologic disease (eg, sickle cell anemia, myelodysplastic syndrome,
hematologic malignancy)
- Current or prior malignancy within 5 years of screening, with the exception of
non-melanoma skin cancers and cervical intraepithelial neoplasia
- Treatment for any malignancy (eg, radiation, chemotherapy, hormone therapy, or
biologics) within 5 years of screening, with the exception of locally excised
non-melanoma skin cancer or cervical intraepithelial neoplasia
- Female subject not willing to use highly effective methods of birth control during
treatment and for 4 weeks after the end of treatment
- Subject is pregnant or breast feeding, or might become pregnant during the study or
within 4 weeks after the end of treatment
- Currently receiving intravenous (IV) antibiotics for treatment of an active infection
- Known Human Immunodeficiency Virus (HIV) positive
- Currently receiving systemic immunosuppressive therapy with the exception of
prednis(ol)one ≤ 10 mg per day (or the steroid equivalent)
- History of any organ transplant
- Currently enrolled in another interventional study (eg, studies which require medical
device use or drug therapy or with protocol required procedures), or less than 4 weeks
since ending another interventional study(s) or receiving investigational agent(s)
- Known neutralizing anti-erythropoietic protein antibodies
- Known sensitivity to any of the products to be administered during dosing
- Previously enrolled in this study
- Not expected to be available for protocol required study visits or procedures to the
best of the subject and investigator's knowledge
- Subject has any kind of disorder that, in the opinion of the investigator, may
compromise the ability of the subject to give written informed consent and/or comply
with all required study procedures
- Occurrence of stroke or myocardial infarction (MI) within 24 weeks of screening
- Receipt of RBC transfusion within 8 weeks of screening
- Occurrence of seizure, clinically relevant active bleeding (eg, gastrointestinal [GI]
bleed) or any hospitalization within 8 weeks of screening
- Receipt of any IV iron therapy within 4 weeks of screening
- Changes in oral iron therapy within 4 weeks of screening
- Receipt of ESA therapy within 4 weeks of screening
- Diagnosis or treatment of malignancy, with the exception of non-melanoma skin cancers
and cervical intraepithelial neoplasia during screening
- Receipt of ESA therapy, RBC transfusions, IV iron therapy during screening
- Changes in oral iron therapy during screening
- Occurrence of stroke, MI, seizure, clinically relevant active bleeding (eg, GI bleed),
any hospitalization or outpatient surgery during screening
- Uncontrolled hypertension during screening. Defined in this study, as a mean systolic
blood pressure > 140 mmHg at both screening visits, or a mean systolic blood pressure
>/= 160 mmHg at any screening visit, or a mean diastolic blood pressure >/= 90 mmHg at
any screening visit.
- Expected or scheduled change in oral iron therapy or receipt of IV iron therapy within
4 weeks after randomization
- Expected or scheduled receipt of a RBC transfusion within 8 weeks after randomization
- Expected or scheduled organ transplant within 24 weeks after randomization
- Expected or scheduled initiation of dialysis within 24 weeks after randomization
We found this trial at
247
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials